| pubmed-article:21361858 | pubmed:abstractText | Two basal insulin analogues, insulin glargine once daily and insulin detemir once or twice daily, are marketed in Canada. Objective: To estimate the long-term costs of insulin glargine once daily (QD) versus insulin detemir once or twice daily (QD or BID) for type 1 (T1DM) and type 2 (T2DM) diabetes mellitus from a Canadian provincial government's perspective. | lld:pubmed |
